Zenyaku Kogyo Co., Ltd. (全薬工業株式会社) is a Japan-based pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human medicines and healthcare products. Its portfolio spans ethical (prescription) pharmaceuticals and consumer/over‑the‑counter products, with activities that include clinical development, regulatory affairs, and nationwide distribution in Japan.
The company’s therapeutic interests include immunology and oncology, among other areas of unmet medical need, and its offerings encompass both small‑molecule drugs and biologics. Zenyaku Kogyo also collaborates with domestic and global partners through licensing, co-development, and co-promotion agreements to introduce innovative therapies to the Japanese market.
None yet. When a new project in the record names Zenyaku Kogyo as owner, partner or investor, it shows here.
Approval adds adult-onset indication with specified IV dosing; Phase III showed 87.4% relapse‑free at Week 49 versus 38.0% for placebo; safety consistent with prior data.
Rituxan co-promotion in Japan ends Sept 3, 2026. One partner will cease sales on sell-out; the other assumes sole sales and medical information from Sept 4. Transition to ensure stable supply.
Rituxan gains approval for treating autoimmune hemolytic anemia, targeting B cells to reduce autoantibodies. Effective for warm AIHA, CAD, and PCH, offering an alternative to steroids.
